NovoCure Ltd — Director's Dealing 2023

Mar 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2023-02-28

Reporting Person: Weinberg Uri (Chief Innovation Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-28	Ordinary Shares	A	12992	—	Acquired	56278	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-28	Options to Buy Ordinary Shares	$76.97	A	21607	Acquired	2033-02-27	Ordinary Shares (21607.0)	Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.

F2: Options to buy 21,607 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.